[Abstract Point-of-collection oral fluids drug-testing devices are being marketed for a variety of medico-legal purposes where they may complement existing technologies and be used to detect drugs following recent ingestion. To assess the utility of these devices for use in drugged-driving investigations, we performed a laboratory evaluation of four devices and those results were published previously. In the study reported here, two more devices, Oratect | (Branan) and Uplink | (OraSure), were evaluated for their ability to detect amphetamines, cocaine, opiates, and cannabinoids. An additional device, Drugwipe (Securtec), was evaluated for the detection of cocaine and cannabinoids. Each of the devices was assessed for their ability to meet the manufacturers' claimed cutoff concentrations and to meet cutoffs proposed for federal workplace programs. In general, the Branan and OraSure devices detected amphetamine, methamphetamine, opiates, and cannabinoid metabolite (THC-COOH) well in the concentration ranges approximating those proposed by the Substance Abuse and Mental Health Services Administration (SAMHSA), but all three devices performed poorly in detecting Ag-tetrahydrocannabinol (THC) at the proposed SAMHSA cutoff. The ability to accurately and reliably detect cocaine was dependent on the individual device, and the Branan and Securetec devices were more effective than OraSure at detecting parent cocaine.
Introduction
In the current environment of increased testing for drugs of abuse in the workplace, treatment programs, judicial system, and schools; there are inherent advantages to point-of-collection (POC) testing and for the selection of oral fluid (OF) as a testing specimen (1, 2) . The collection of OF can be observed and is generally considered less invasive than collecting either blood or urine (3) . The detection times for drugs of abuse in OF approximate those of blood, and OF usually contains parent drug rather than the drug metabolites that are generally detected in urine. Therefore, OF drug concentrations are better indicators of recent use and of more interpretative value than urinary drug concentrations. However, testing OF for drugs of abuse is relatively new, and the detection and interpretation of drugs in this medium can depend on many factors such as OF/plasma drug ratio, pH, method of collection, and expected drug concentration (4, 5) . In a previous publication, we reported the performance of four commercially available devices based on the manufacturers' claims and proposed workplace cutoff concentrations (4) . The purpose of the current publication is to report the results of our evaluation of two additional devices the Oratect (Branan Medical Corporation, Irvine, CA) and Uplink (OraSure Technologies Inc., Bethlehem, PA) for the detection of amphetamine, methamphetamine, cocaine, opiates (morphine), A9-tetrahydrocannabinol (THC), and 11-carboxy-THC (THC-COOH). In addition, we evaluated Drugwipe (Securetec, Ottobrunn, Germany) for the detection of cocaine and cannabinoids. The devices were evaluated in a laboratory setting to determine their accuracy and reliability when challenged with OF samples fortified with known concentrations of the selected drugs.
Methods
The evaluations were performed jointly by The Walsh Group (TWG, Bethesda MD) and the Center for Human Toxicology (CHT) at the University of Utah (Salt Lake City, UT) using procedures detailed previously (4) . Using the manufacturers' product information and the Substance Abuse and Mental Health Services Administration (SAMHSA)'s draft guidelines (6, 7) , target drug concentrations for the evaluation controls were established. In general, the devices were challenged with drug-free (negative, n ---5) and n = 10 of low (~1/2X), medium (~2X), and high (~10X) controls based on the proposed SAMHSA OF-cutoff concentrations. Device sensitivity dictated that THC low, medium, high, and extra-high (xhigh) controls be fortified at 1.25X, 5X, 12.5X, and 25X, respectively, the pro-posed SAMHSA cutoff concentration for THC. For a similar reason, THC-COOH control concentrations were fortified at 2.5x, 12.5x, and 25x the proposed SAMHSA cutoff. Concentrations of the control solutions were verified (• 10%) by mass spectrometry (4) . Controls were provided to the analysts encoded with a number such that they were tested in a "blind to the analyst fashion" as described previously (4) .
Each manufacturer was invited to provide on-site training for the proper use of their devices. The analyses were then performed according to the manufacturers' written and verbal instructions. For the Branan and Securetec devices, in which the results were visually interpreted, two analysts (primary and secondary) read and recorded the result. After the analysts results were summarized, the data were evaluated based on "expected result" given the device cutoff and the control concentration. The results were categorized as true positive (TP), true negative (TN), false positive (FP), or false negative (FN).
Results
As discussed, there currently are no "standard" cutoff concentrations for the detection of drugs in OF. Further, for most drugs, there were significant differences in the cutoffs between the devices. Therefore, we choose to evaluate the devices against the manufacturers' published cutoffs and used the proposed SAMHSA OF-cutoffs as a guide for selecting the control concentrations. Table I shows the target analytes, fortified control concentrations, and assayed control concentrations. Only the medium cocaine control concentration exceeded + 10% of its target value. Tables II-IV show the drug class, device target analyte and cutoff, control concentration, expected result, and whether the result was a TP, TN, FP, or FN.
No discrepancies between the primary and secondary interpretation of the results as positive or negative were observed for the Branan and Securetec devices, indicating a lack of ambiguity of the results. Table II presents the results from the Branan device evaluation. There were no errors for the detection of opiates and cocaine. Results for methamphetamine and amphetamine below the device's cutoff were variable, but error-free above the cutoff. Theoretically, a positive result was anticipated with the xhigh THC control. However, the control assayed concentration was less than 100 ng/mL (92.9 ng/mL); therefore, the FN negative classification of those results may not be warranted. The device performed without error for the detection of THC-COOH. Figure I illustrates the Branan device's performance relative to the proposed SAMHSA cutoff concentrations. The device demonstrated sensitivity for opiates at one-half of the proposed SAMHSA cutoffs (6, 7) . Also, the device was able to detect amphetamine and methamphetamine in controls that bracketed the proposed SAMHSA 50 ng/mL stimulant cutoff. The device performed well at the medium (40 ng/mL) concentration for cocaine (2x the proposed SAMHSA cutoff). However, the device was unable to detect THC at the concentration proposed by SAbIHSA. Table III shows the OraSure device performed error-free at the manufacturer's cutoffs for methamphetamine and opiates. The device showed good sensitivity for the detection of amphetamine near its cutoff with 80% of the challenges testing positive at 25 ng/mL. However, nine FN results were observed for cocaine at the highest control concentration of 200 ng/mL. The device performed error-free for THC and THC-COOH at control concentrations above the manufacturer's 25 ng/mL cutoff, but 10 FP were recorded for THC-COOH at 10 ng/mL. Figure 2 shows the OraSure device's performance relative to the proposed SAMHSA cutoff concentrations. The figure shows that the device effectively detected methamphetamine, amphetamine, and opiates at concentrations that were one-half of the proposed cutoffs. Cocaine was not effectively detected even at concentrations 10x the proposed SAMSHA cutoff. The device was able to differentiate between the medium (20 ng/mL) and high (50 ng/mL) controls for THC, but was unable to detect concentrations approaching the 4 ng/mL proposed SAMHSA cutoff. However, THC-COOH was detected at 10 ng/mL. at the manufacturer's stated cutoffs for cocaine, THC, and THC-COOH. Performance for the detection of alternate drugs of abuse was published previously (4) . Figure 3 shows the Securetec device's performance relative to the proposed SAMHSA cutoff concentrations for cocaine, THC, and THC-COOH. The figure shows that the device was not effective in detecting cocaine at concentrations 2x the proposed cutoff. Also, the device did not detect THC until the control concentration was at least 50 ng/mL. The device has published sensitivity to 3 ng/mL of THC-COOH, but was not challenged at that concentration.
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Discussion
A significant finding from the two evaluations was that no negative control samples tested positive (no actual FN results). However, the overall performance of the POC-OF drug-testing devices reported here was variable and similar to those reported earlier in that some devices performed well for the analysis of certain drugs or drug classes, but poorly for others (4) . In general, most of the devices in the two studies detected methamphetamine, amphetamines, opiates, and THC-COOH well, and they detected those drugs in the range of the cutoff concentrations proposed by SAMHSA. However, their ability to accurately and reliably detect cocaine was device dependent. For example, the Branan and Securetec devices performed as predicted. However, the OraSure device was designed to target benzoylecgonine (10 ng/mL), and although it was ineffective at detecting cocaine, it performed accurately when challenged at 0, 5, and 25 ng/mL of benzylecgonine (n --2, data not shown). All devices performed poorly in detecting THC in the range proposed by SAMHSA and at physiologically relevant concentrations. The best sensitivity was that of OraSure (25 ng/mL), followed closely by Securetec (30 ng/mL). However, most devices were not designed to detect THC at concentrations < 100 ng/mL. This remains a key concern with the use of POC-OF devices because marijuana is commonly abused in the United States, and for most testing applications (e.g., workplace, criminal justice, drugs/driving, etc.), the ability to detect its recent use is critical. tions. THC and THC-COOH low controls were 5 ng/mL and 10 ng/mL, respectively, and were above the proposed SAMHSA cutoff of 4 ng/mL. THC and THC-COOH low controls were 5 ng/mL and 10 ng/mL, respectively, and were above the proposed SAMHSA cutoff of 4 ng/mL. .=. tions. THC and THC-COOH low controls were 5 ng/mL and 10 ng/mL, respectively, and were above the proposed SAMHSA cutoff of 4 ng/mL.
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